Total pharma deals worth $21.11bn were announced during Q4 2018, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The value marked a decrease of 6.32% over the previous quarter and a drop of 64.84% when compared with the last four-quarter average of $60.07bn.
In terms of number of deals, the sector saw a drop of 7.18% over the last four-quarter average with 388 deals against the average of 418 deals.
In value terms, North America led the activity with deals worth $16.64bn.
The top announced deal, as tracked by GlobalData, in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe article considers only announced and completed deals from the GlobalData Financial Deals database and excludes all terminated and rumoured deals. GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
